Suicide gene therapy of rhabdomyosarcoma

Konieczny,Paweł; Sułkowski,Maciej; Badyra,Bogna; Kijowski,Jacek; Majka,Marcin

doi:10.3892/ijo.2016.3824

Suicide gene therapy of rhabdomyosarcoma

Authors:
- Paweł Konieczny
- Maciej Sułkowski
- Bogna Badyra
- Jacek Kijowski
- Marcin Majka
View Affiliations

Affiliations: Department of Transplantation, Faculty of Clinical Immunology and Transplantation, Jagiellonian University Medical College, 30-663 Krakow, Poland
Published online on: December 29, 2016 https://doi.org/10.3892/ijo.2016.3824
Pages: 597-605

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood and young adulthood. Conventional treatment consisting of surgery, chemotherapy and radiotherapy can be insufficient, as long-term survival chances decrease dramatically when cancer recurrence occurs. Due to this fact, efficient treatment of this cancer is still a demanding issue, thus, novel and innovative therapies have to be considered as a part of combined treatment. In the present study, we present effective suicide gene therapy of rhabdomyosarcoma cell line Rh30 involving herpes simplex thymidine kinase (HSV-TK) and ganciclovir (GCV). Transduction of rhabdomyosarcoma cells using lentiviral vectors allowed efficient introduction of HSV-TK gene. In this study we proved high susceptibility of modified cells to ganciclovir resulting in eradication of cancer cells both in vitro and in vivo. Our data revealed strong gap junctional intercellular communication in examined cell line responsible for elimination of unmodified cells by bystander effect, even if HSV-TK-expressing cells comprise only 20% of cultured cells. Moreover, investigated approach is also efficient in vivo, where complete remission of tumors upon only 14 days of systemic administration of GCV can be observed. Obtained results suggest that HSV-TK suicide gene therapy is very promising concept in future clinical studies concerning rhabdomyosarcoma.

View Figures

View References

1	O'Brien D, Jacob AG, Qualman SJ and Chandler DS: Advances in pediatric rhabdomyosarcoma characterization and disease model development. Histol Histopathol. 27:13–22. 2012.
2	Ognjanovic S, Linabery AM, Charbonneau B and Ross JA: Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer. 115:4218–4226. 2009. View Article : Google Scholar : PubMed/NCBI
3	Geltzeiler M, Li G, Abraham J and Keller C: The case for primary salivary rhabdomyosarcoma. Front Oncol. 5:742015. View Article : Google Scholar : PubMed/NCBI
4	Kashi VP, Hatley ME and Galindo RL: Probing for a deeper understanding of rhabdomyosarcoma: Insights from complementary model systems. Nat Rev Cancer. 15:426–439. 2015. View Article : Google Scholar : PubMed/NCBI
5	Parham DM and Ellison DA: Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med. 130:1454–1465. 2006.PubMed/NCBI
6	Malempati S and Hawkins DS: Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 59:5–10. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kashima K, Watanabe M, Sato Y, Hata J, Ishii N and Aoki Y: Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4. Cancer Sci. 105:1343–1350. 2014. View Article : Google Scholar : PubMed/NCBI
8	Kokoris MS and Black ME: Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci. 11:2267–2272. 2002. View Article : Google Scholar : PubMed/NCBI
9	Nicholas TW, Read SB, Burrows FJ and Kruse CA: Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol Histopathol. 18:495–507. 2003.PubMed/NCBI
10	Andrade-Rozental AF, Rozental R, Hopperstad MG, Wu JK, Vrionis FD and Spray DC: Gap junctions: The 'kiss of death' and the 'kiss of life'. Brain Res Brain Res Rev. 32:308–315. 2000. View Article : Google Scholar : PubMed/NCBI
11	Peiris TH and Oviedo NJ: Gap junction proteins: Master regulators of the planarian stem cell response to tissue maintenance and injury. Biochim Biophys Acta. 1828:109–117. 2013. View Article : Google Scholar
12	Nielsen MS, Axelsen LN, Sorgen PL, Verma V, Delmar M and Holstein-Rathlou NH: Gap junctions. Compr Physiol. 2:1981–2035. 2012.
13	Czyż J, Irmer U, Schulz G, Mindermann A and Hülser DF: Gap-junctional coupling measured by flow cytometry. Exp Cell Res. 255:40–46. 2000. View Article : Google Scholar
14	Di Ianni M, Di Florio S, Venditti G, Falzetti F, Mannoni P, Martelli MF and Tabilio A: T lymphocyte transduction with herpes simplex virus-thymidine kinase (HSV-tk) gene: Comparison of four different infection protocols. J Hematother Stem Cell Res. 8:645–652. 1999. View Article : Google Scholar
15	Mesnil M and Yamasaki H: Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res. 60:3989–3999. 2000.PubMed/NCBI
16	You Y: Targets in Gene Therapy. InTech. 2011, http://dx.doi.org/10.5772/1012.
17	Neschadim A, Wang JC, Lavie A and Medin JA: Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. Cancer Gene Ther. 19:320–327. 2012. View Article : Google Scholar : PubMed/NCBI
18	Veldwijk MR, Berlinghoff S, Laufs S, Hengge UR, Zeller WJ, Wenz F and Fruehauf S: Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors. Cancer Gene Ther. 11:577–584. 2004. View Article : Google Scholar : PubMed/NCBI
19	Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ and Blaese RM: Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 6:57–62. 1999. View Article : Google Scholar : PubMed/NCBI
20	Tseng JC, Zanzonico PB, Levin B, Finn R, Larson SM and Meruelo D: Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med. 47:1136–1143. 2006.PubMed/NCBI
21	Lin Z, Zhang Z, Han Y, Naus CC, Yu KR and Holtzer H: Functional expression of gap junction gene Cx43 and the myogenic differentiation of rhabdomyosarcoma cells. Sci China B. 38:305–312. 1995.PubMed/NCBI
22	Mesnil M: Connexins and cancer. Biol Cell. 94:493–500. 2002. View Article : Google Scholar
23	Garcia-Rodríguez L, Pérez-Torras S, Carrió M, Cascante A, García-Ribas I, Mazo A and Fillat C: Connexin-26 is a key factor mediating gemcitabine bystander effect. Mol Cancer Ther. 10:505–517. 2011. View Article : Google Scholar : PubMed/NCBI
24	Sanson M, Marcaud V, Robin E, Valéry C, Sturtz F and Zalc B: Connexin 43-mediated bystander effect in two rat glioma cell models. Cancer Gene Ther. 9:149–155. 2002. View Article : Google Scholar : PubMed/NCBI
25	Tanaka M, Fraizer GC, De La Cerda J, Cristiano RJ, Liebert M and Grossman HB: Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery. Gene Ther. 8:139–148. 2001. View Article : Google Scholar : PubMed/NCBI
26	Ciurea ME, Georgescu AM, Purcaru SO, Artene SA, Emami GH, Boldeanu MV, Tache DE and Dricu A: Cancer stem cells: Biological functions and therapeutically targeting. Int J Mol Sci. 15:8169–8185. 2014. View Article : Google Scholar : PubMed/NCBI
27	CYTOVENE^® Product Monograph. http://www.rochecanada.com/en/products/pharmaceuticals/consumerinformation/cytovene.html.
28	van Dillen IJ, Mulder NH, Vaalburg W, de Vries EFJ and Hospers GAP: Influence of the bystander effect on HSV-tk/GCV gene therapy. A review Curr Gene Ther. 2:307–322. 2002. View Article : Google Scholar